Dianthus Therapeutics DNTH Cash Flow Statement
| TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | TTM Q4 '24 | TTM Q3 '24 | ||
|---|---|---|---|---|---|---|
| -$126.35M-10.1% | -$114.75M-13.9% | -$100.73M-18.6% | -$84.97M-26.6% | -$67.09M-18.4% | ||
| $110K+1.9% | $108K+6.9% | $101K+5.2% | $96K+6.7% | $90K+7.1% | ||
| $20.73M+10.4% | $18.78M+16.1% | $16.17M+25.4% | $12.89M+32.9% | $9.7M+37.8% | ||
| -$109.52M-9.3% | -$100.23M-10.3% | -$90.87M-16.2% | -$78.18M-24.9% | -$62.59M-22.0% | ||
| $106K-15.9% | $126K+29.9% | $97K-7.6% | $105K+25.0% | $84K— | ||
| -$183.15M+24.1% | -$241.24M+9.9% | -$267.68M+7.0% | -$287.98M— | —— | ||
| $314.92M+674% | $40.7M+1.4% | $40.13M-84.4% | $257.82M+18.2% | $218.14M-38.8% | ||
| —— | —— | -$319.44M-192% | -$109.37M— | —— | ||
| -$109.63M-9.2% | -$100.36M-10.3% | -$90.97M-16.2% | -$78.29M-24.9% | -$62.67M-22.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Dianthus Therapeutics's cash flow data come from?
- Every line is extracted from Dianthus Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.